Tuberculin

Summary

Tuberculin (CHEMBL2108161) is a phase-3 clinical-stage unknown (ATC V04CF01); indicated across 3 conditions including anogenital human papillomavirus infection and common wart.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: V04CF01
• Indications: 3 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108161
Name	Tuberculin
Type	Unknown
Max phase	3
ATC	V04CF01

Also known as: Tuberculin, Tuberculin ppd, old, purified protein derivative of, Tuberculinum, TUBERCULIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anogenital human papillomavirus infection	3	MONDO:0005647	EFO:0007147
common wart	3	MONDO:0001209	EFO:0009662
tuberculosis	3	MONDO:0018076	MONDO:0018076

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
Not specified	4
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03153566	PHASE3	UNKNOWN	Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients
NCT00128193	PHASE2	COMPLETED	Leprosy Skin Test Antigens Trial
NCT01910662	PHASE1	COMPLETED	Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)
NCT00716989	Not specified	TERMINATED	Pathophysiological Study of Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections
NCT02090374	Not specified	COMPLETED	Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
NCT04073108	Not specified	UNKNOWN	Causes of FUO in Infants and Children
NCT04347876	Not specified	UNKNOWN	Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).